Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.

Martin Boegemann,Jens Bedke,Martin Schostak,Christiane Hering-Schubert,Manfred Welslau,J. Schleicher,Thomas Wolf,Alexander Petzoldt,Christian Doehn,Carsten Grüllich,Viktor Grünwald,Thomas Steiner,Anja Rogler,Sven Hanson,Dunja Klein,Tanja Medinger,P. J. Goebell

Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.

2019

Martin Boegemann
Jens Bedke
Martin Schostak
Christiane Hering-Schubert
Manfred Welslau
J. Schleicher
Thomas Wolf
Alexander Petzoldt
Christian Doehn
Carsten Grüllich
Viktor Grünwald
Thomas Steiner
Anja Rogler
Sven Hanson
Dunja Klein
Tanja Medinger
P. J. Goebell

4574Background: Randomized clinical trials for the implementation of new therapies include only a selection of patients that are later treated with these new options. Thus, real-world evidence is u...

Keywords:

Interim
Sequential treatment
Nivolumab
Renal cell carcinoma
Pazopanib
Pathology
Oncology
Internal medicine
Medicine
in patient
non interventional
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations